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SUMMARY
Colorectal cancer is the 3rd most common malignant neoplasm in the West. About 50% 
of patients develop liver metastases throughout the course of the disease. Those are res-
ponsible for at least two-thirds of deaths. Advances in surgical techniques and improve-
ment in chemotherapy regimens have allowed offering treatment with curative intent to 
an increasing number of patients. This article reviews recent advances in the treatment 
of liver metastases, including strategies to increase resection (e.g., portal vein emboliza-
tion, radiofrequency ablation, two-stage hepatectomy, conversion therapy and reverse 
treatment strategy) and hepatectomy in the presence of extrahepatic disease. Finally, the 
results of surgical treatment of liver metastases at the Hospital A.C. Camargo are briefly 
shown. 
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INTRODUCTION
Colorectal cancer is the 3rd most common malignant neo-
plasm in the West. Approximately 50% of the patients de-
velop liver metastasis during the disease evolution, which 
are responsible for at least two-thirds of the deaths1-6. To 
date, the only potentially curative therapy for these pa-
tients is the surgical treatment. However, only 10% to 20% 
are candidates to resection. When patients are submitted 
to complete resection, the flve-year survival can range 
from 37% to 58% in the most recent series6-8.
Although only some of these patients are candidates 
to surgical treatment, the absolute number of resectable 
individuals is signiflcant. If a free estimate is made for the 
Brazilian population, based on the incidence rates sup-
plied by the National Cancer Institute (Instituto Nacional 
do Cancer – INCA) for colorectal cancer in 2009/2010, 
which is 27,000 new cases/year, one can suppose that 
around 13,500 (50%) patients have or will have colorec-
tal liver metastases (CRLM), of which 2,700 to 4,050 pa-
tients/year (20% to 30%) will be potential candidates for 
liver resections. 
The increase in the number of surgical indications, 
with the inclusion of bilateral metastases, with no lim-
it for the number and size of nodules, associated with 
the improvement in systemic treatment outcomes with the 
use of new regimens with high response rates (going from 
less than 20% to approximately 50%), can change patients 
that were initially unresectable into resectable ones and 
treatments that were initially palliative into curative ones9-11. 
The present article reviews the recent advances in the 
treatment of liver metastases, including strategies to increase 
resection and hepatectomies in the presence of extrahepatic 
disease. Finally, we briefly show the results of the surgical 
treatment of liver metastases in Hospital A.C. Camargo.
RESECTABILITY CRITERIA 
The capacity to remove all liver metastases with free margins 
and preserve a future remnant liver (FRL) of at least 20% of 
the total liver volume (TLV) in patients with a healthy liver, 
in the absence of unresectable extrahepatic disease, deflnes 
most cases regarding liver resectability. Moreover, it is nec-
essary to guarantee adequate arterial and portal inflow, as 
well as biliary drainage and venous return (outflow). Some 
patients might need a FRL volumefl>fl20%. 
Patients that have been submitted to many chemother-
apy cycles (intensive chemotherapy) need FRL of at least 
30%, whereas for patients with chronic hepatopathy one 
can estimate 40%. There is still a great deal of controversy 
regarding what is considered intensive chemotherapy. In 
Hospital A. C. Camargo, that is considered as more than 
six cycles of the usual regimen carried out currently, such 
as FOLFOX (5-Fluorouracil and oxaliplatin), FOLFIRI 
(5-Fluorouracil and irinotecan) or FOLFOXIRI (5-Fluoro-
uracil, oxaliplatin and irinotecan).
In patients candidate to extensive resections, it is nec-
essary to calculate with higher accuracy the FRL volume. 
For that purpose, it is necessary to perform liver volum-
etry. The direct measurement of the FRL is performed by 
computed tomography (CT). Among the existing formu-
las, we used the one described by Vauthey et al. to calculate 
the standardized total liver volume12-13 (Figurefl1).
As for the margin, differently from what was believed 
in the past, a margin of at least 1flcm is not mandatory. 
Busquets et al.14 in a multicentric study with 557 patients, 
compared the resection margins from 1flmm to 1flcm and 
observed that there was no signiflcant difference in global 
and free-of-disease survival. Therefore, the main objective 
is to achieve free margins, even though the goal is a 1-cm 
margin14. 
PREOPERATIVE EVALUATION AND STAGING EXAMINATION
Initially, the sequelae of previous treatments (for in-
stance, previous hepatectomy and chemotherapy) must 
be considered as well as patients’ comorbidities (obesity, 
diabetes mellitus, alcohol consumption, liver cirrhosis). 
The morbidity associated with liver steatosis, very oflen a 
consequence of the systemic treatment, is a controversial 
issue, as although there is a histological liver lesion, its 
influence on mortality remains controversial15.  
The main examination to be carried out for the stag-
ing is the CT with a protocol for liver, where thin-section 
CT images are acquired (preferably in equipment with 
multidetectors) in four phases: pre-contrast, arterial, 
portal and equilibrium or late phase. It is considered the 
gold-standard by most specialized centers, as it allows 
the accurate assessment of resectability, the number of 
nodules and their association with liver structures and 
adjacent organs, in addition to performing the liver volu-
metry. 
Other examinations can also be effectively per-
formed, especially the magnetic resonance (MR), which 
allows the acquisition of images that are equivalent to the 
tomography in terms of quality. Some believe that at this 
time of preoperative chemotherapy and obesity, the MR 
can be very important, due to the higher capacity of dif-
ferentiating areas of steatosis from secondary nodules, 
which has yet to be deflnitively demonstrated. 
The colonoscopy must be always used to rule out the 
possibility of primary tumor recidivism. Chest images by 
x-rays or CT are also mandatory to assess the presence of 
lung metastases. 
The positron emission tomography (PET)-CT is the 
new tool for the staging of these patients, but there is no 
consensus on its use to date. Fernandez et al. 16 evaluated 
100 patients with liver metastases of colorectal origin that 
were submitted to PET-CT in the preoperative period and 
concluded that there are survival advantages when the 
18F-Fluorodeoxyglucose (FDG) PET/CT is used, due to 
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better patient selection for surgery, with a 5-year survival 
of 58% being observed in this group of patients; however, 
the great criticism faced by this study is not comparing 
PET-CT with the currently available high-denition to-
mographic images. One must be aware of false-negative 
results aer the chemotherapy. Thus, even when there 
is no uptake of a nodule visualized before the chemo-
therapy, the indication for resection is maintained, as the 
decreased sensitivity of PET-CT in detecting metastases 
post-chemotherapy is well-known17, mainly before two 
weeks aer its completion. 
The PET-CT can also predict the response to chemo-
therapy when 18F-FU is used instead of 18F-FDG18.
One of the most important questions regarding the 
re-staging post-chemotherapy is the discrepancy be-
tween imaging study results and surgical ndings19,20. 
Angliviel et al.20 showed that there is more than 50% of 
result discrepancy in CT ndings post-chemotherapy at 
the re-staging when compared with the surgical ndings. 
Carnaghi et al.19 pointed out that both PET-CT and CT 
have limited sensitivity (60%) for re-staging of CRLM 
post-chemotherapy, especially for lesions <1cm. 
Benoist et al.21 evaluated 66 patients that had com-
plete response at the imaging examinations aer “neo-
adjuvant” chemotherapy and were submitted to surgical 
exploration and systematic clinical follow-up. Of these, 
32 had lesions identied at the surgery and 23 were iden-
tied at the clinical follow-up in the same sites of the pre-
vious lesion. The conclusion is that 83% of the patients 
that had a complete response at the imaging examina-
tions have macro or microscopic residual disease or early 
recidivism. From our point of view, this information is of 
utmost importance for the indication of surgical explora-
tion and resection of previously compromised areas, even 
in patients in whom complete radiological response was 
observed and for whom a curative treatment is intended. 
SURGICAL TREATMENT
The surgical procedure must be initiated with the sys-
tematic exploration of the abdominal cavity, with spe-
cial attention when assessing the presence of extra-
hepatic disease. Colon, peritoneum, retroperitoneal 
lymph nodes, celiac trunk and hepatic hilum are evalu-
ated and biopsies and microscopic examination of fro-
zen samples are carried out in all suspected sites. 
All assessment modalities are important during liver 
evaluation. The presence of nodules, post-chemothera-
py scars, retractions or areas suggestive of fibrosis must 
be observed. At palpation, the presence of hardened, 
round, firm, or fibroelastic areas that can be superfi-
cial, easily palpable or deep can be noticed. These must 
be assessed carefully, as the presence of the liver paren-
chyma between the tumor and the examiner’s hand can 
make the evaluation difficult. The examination must 
be carried out by surgeon by sliding the hands over the 
entire liver surface and it must always be bimanual, in-
creasing the sensitivity to identify deep lesions, espe-
cially in the left lobe. 
The intraoperative ultrasonography is currently an 
essential tool for staging and surgical planning and 
therefore, a mandatory examination in any liver sur-
gery. It can identify 20% to 30% of the nodules that were 
not detected at the conventional examinations. In our 
country, Cohen MP et al.22 demonstrated that the in-
traoperative ultrasonography in surgeries performed to 
resect liver metastases changes the surgical strategy in 
25.7% of the cases and is extremely useful in identifying 
lesions <1cm.
The type of resection must guided by the number 
and location of lesions and by the need to attain tumor-
free margins. The anatomic resections, that is, exeresis 
of liver segments or lobes, respecting the regions de-
limited by venous and arterial vascularization, in addi-
tion to the biliary drainage, are preferable, as they allow 
lower blood loss and carry a lower risk of compromised 
margins. However, there is no difference in survival re-
garding the non-anatomical resections, as long as the 
margins are free23,24. The types of resection are: segmen-
tectomies, bi-segmentectomies, central hepatectomies, 
lobectomies, tri-segmentectomies, enucleations and 
combinations of these forms. Resections that are con-
comitant to the primary tumor are safe and feasible, as 
long as they are carried out by an experienced tem and 
follow the oncologic principles.  
STRATEGIES TO INCREASE RESECTABILITY
As previously described, resectability is currently de-
fined by a new paradigm, where the possibility of re-
section of liver lesions must be considered, as  well as 
the complete resection of extrahepatic lesions and the 
quality (inflow-outflow) and quantity of remnant liver 
after the surgery and not exclusively by the tumor clini-
copathological factors. Therefore, previously used cri-
teria, such as number of nodules, size of lesions, bilat-
eralism and presence of extrahepatic disease (as long as 
resectable) must be considered prognostic factors and 
not a contraindication for resection. 
BEFORE: based on what was resected.
CURRENTLY: based on what will remain aer resection. 
Based on these principles, strategies are defined, 
which will allow the resection of extensive disease in 
several circumstances where they would previously be 
considered unresectable. Still, there are cases in which 
complete resection with FRL volume cannot be attained 
with the usual techniques. In this situation, other tech-
niques are employed to increase resectability. 
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PORTAL VEIN EMBOLIZATION
In general, 20% of the normal FRL is considered safe aer 
an extensive resection.  However, the sectioning volume 
for FRL in patients with livers presenting steatosis, steato-
hepatitis (30% RLV) or cirrhosis (>40%) must be higher. 
In general, the right lobe represents two-thirds of the liver 
volume and the le only one-third. Frequently, patients with 
multiple liver lesions are submitted to right hepatectomy ex-
tended to segment IV (or right tri-segmentectomy). 
On average, these surgeries remove around 84% of the 
liver volume in the absence of compensatory hypertrophy 
of the remnant liver25. However, a high degree of indi-
vidual variation can be observed in the volumes of liver 
segments and lobes. To prevent surgeries in patients with 
FRL lower than the desired volume, the portal vein embo-
lization must be carried out to induce contralateral lobe 
hypertrophy25. 
The idea came from the observation that when 
there is invasion of a portal vein branch by the tumor, there 
is hypertrophy of the contralateral lobe. Technically it is 
performed through catheterization by radioscopy of the 
lobe or segmental vein, followed by vessel embolization 
by embolic material (coils, thrombin, cyanoacrylate, mi-
crospheres, etc). It is a relatively safe procedure; its rate of 
complications varies from 5% to 8%. Then expected vol-
ume growth of the FRL is of 8% to 16%26-28. 
The portal vein embolization is more frequently used 
as part of the multimodal treatment regimens, which in-
clude preoperative chemotherapy and hepatectomy, as 
most part of these patients already presents with more 
than one factor of poor prognosis, such as multiple lesions, 
bilobar lesions, compromised lymph nodes at the primary 
and extrahepatic metastases. 
 Some authors evaluated whether the use of CT before 
or aer the portal embolization could impair liver hyper-
trophy; however, the results showed no impairment in 
liver hypertrophy when volume increase is desired29,30.
TWO-STAGE HEPATECTOMY 
In extreme situations, in which there are multiple metas-
tases in both hepatic lobes, two-stage resections can be the 
best therapeutic option and the only chance of cure, pre-
serving an adequate volume of FRL. 
The initial results had a high rate of liver failure and 
postoperative mortality >fl10%31, very different from what 
is currently observed with the routine use portal vein em-
bolization in specialized centers. 
The recommendation is that at the flrst intervention, 
the removal of the liver metastasis be carried out in the 
liver parenchyma that one wishes to preserve (FRL), to 
prevent the excessive growth of metastases afler the portal 
flow deviation by embolization. It is usually a parenchyma-
sparing resection carried out in the lobe or segments that 
exhibit less disease damage (usually the lefl lobe) attaining 
tumor-free margins, and allowing the preservation of most 
of the lobe or segments in question. There is a 4-to-6 week 
interval to surgery and volumetry control is always per-
formed before and afler this period, to ensure that there is 
FRL with an adequate volume.
At the second stage of the procedure, a more extensive 
resection is performed, most oflen from the right lobe, 
which extends to the IV segment. It is seldom necessary to 
perform lefl portal vein embolization for right lobe hyper-
trophy, as the volume of the latter is hardly ever lower than 
the desired volume. As it is a complex procedure, it must 
be performed only in curative situations. 
In several situations, CT is indicated during the time 
between the embolization and surgery, without the use 
of monoclonal antibody (Bevacizumab), when it is being 
used in the CT regimen. The objective is to prevent tumor 
growth during the period when waiting for the second 
phase of the surgery. 
RADIOFREQUENCY 
Another alternative to the two-stage surgery is the asso-
ciation of radiofrequency (RF) ablation with liver resec-
tion, which in some situations can expand the number of 
patients eligible for surgery. However, the RF has a higher 
risk of recidivism in comparison with the resection, main-
ly in lesions > 3flcm. It use must be restricted to cases in 
which the resection is not possible due to lack of adequate 
FRL volume7. 
CONVERSION THERAPY 
Many patients have such extensive liver disease at diag-
nosis that they cannot be candidates to liver resection 
through any of the strategies mentioned before. However, 
there are cases in which the reduction of hepatic lesions 
through CT can enable the surgical treatment, transform-
ing an initially unresectable disease into a resectable one. 
When the CT is used for that purpose, it is called conver-
sion chemotherapy. 
The conversion CT consists of administration of thera-
peutic regimens with a high rate of response, aiming at the 
decrease in tumor volume to allow the resection of metas-
tases, while obtaining an adequate liver volume. 
The main therapeutic options are FOLFOX or FOL-
FIRI, or a combination of both (FOLFOXIRI), with re-
sponse rates of 48-66%32-35, 39-62%36-38 and 56-71,4%39,40, 
respectively. According to some authors, there is a “con-
version” in around 10% to 20% of individuals initially con-
sidered to unresectable9, with survival rates similar to that 
observed in patients that are initially resectable41. Higher 
response rates can be obtained by adding target-therapy 
with cetuximab or bevacizumab.
CT duration must be only the necessary time for con-
version to occur, with no predetermined number of cycles. 
The intention is to submit the patient to surgery as soon 
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as the lesions are resectable, preventing unnecessary liver 
toxicity that result from CT excess and also an eventual 
progression of the disease aer a long period of treatment. 
Thus, the patients must be followed together with the 
surgeon, through control image assessment every two 
months, aiming at detecting lesion response and identify-
ing, as soon as possible, the moment when the metastases 
become resectable. If there is no adequate radiological re-
sponse, a new CT scheme can be attempted, always aiming 
at conversion. 
EXTRAHEPATIC DISEASE
Traditionally, the presence of extrahepatic metastases of 
colorectal origin was considered an absolute contraindi-
cation for hepatectomy42. As a consequence of safer sur-
gical procedures and the evolution of the effectiveness of 
CT schemes, hepatic resections started to be performed 
in association with extrahepatic metastasis resection, for 
selected groups of patients. The main sites of extrahepatic 
disease to be considered are: portal lymph nodes, perito-
neum and lungs.
The metastases for portal lymph nodes in the context of 
CRLM result from the lymphatic drainage of the liver and 
thus, represent the local-regional dissemination of liver 
metastases43. Patients with macroscopic metastases for por-
tal lymph nodes have an unfavorable evolution, with little 
chance of flve-year survival44,45. However, it is possible to 
select patients with a better prognosis based on the loca-
tion of the affected lymph nodes. Jaeck et al.46 demonstrated 
that whereas patients with lymph node metastases along the 
common hepatic artery and celiac trunk have 0% 1-year 
survival, those with lymph node metastases located in the 
hepatoduodenal ligament had a 38% 3-year survival. These 
flndings were conflrmed by Adam et al.47, who showed a 
5-year survival of 25% in the analysis of 47 patients with 
peri-hepatic lymph node metastases in the hepatoduode-
nal ligament, whereas there were no survivors among those 
with metastases in the celiac or para-aortic trunk. 
Therefore, only patients with hepatoduodenal ligament 
lymph node metastasis must be considered for liver resec-
tion. Those with retroperitoneal lymph node disease must 
receive palliative treatment. 
The lungs, together with the liver, are the most com-
mon sites of metastases in colorectal tumors. Several stud-
ies have demonstrated that the resection of the lung dis-
ease can lead to long-term survival48. However, little has 
been studied on the presence of synchronic lung and liver 
metastases. Six studies addressed this question, showing 
that although it is oflen necessary to perform new resec-
tions per early recidivism, the global 5-year survival var-
ies from 27-74%49. The main factors that seem to influence 
prognosis are: number of pulmonary lesions, number of 
hepatic lesions and the synchronic versus metachronic 
presentation.  
Peritoneal carcinomatosis occurs in 13-25% of pa-
tients with colorectal tumors. If treated only with sys-
temic CT, this condition leads to death in less than one 
year, with a median survival ranging from 5.2 to 6.9 
months50. However, similarly to hepatic metastases, it is 
believed that it does not always represent disseminated 
systemic disease, but a local-regional form of dissemi-
nation (transmural deposit of tumor cells), which can 
be treated by peritonectomy and hyperthermic intra-
peritoneal chemotherapy (HIPEC)51. Thus, patients with 
restricted peritoneal disease can beneflt from this treat-
ment52. Two studies speciflcally addressed the association 
between peritoneal carcinomatosis and liver metastases. 
Carmignani et al.53 evaluated 27 patients with peritoneal 
carcinomatosis, of which 16 had liver metastases as the 
only additional site of the disease and 4 other had liver 
and lung metastases. The procedures aiming at complete 
cytoreduction had a morbidity of 14.8%, with no deaths 
and a median survival of 15.2%. Elias et al. reported on 
the treatment of 27 patients with CRLM and synchronic 
peritoneal carcinomatosis, of which 14 patients had car-
cinomatosis detected preoperatively and 13, intraopera-
tively54. There was a postoperative death (4%) on 14th day 
due to undiagnosed peritonitis and the morbidity was 
58%. With a median follow-up of 6.1 years, the global 
5-year survival was 26.5%, with seven patients being 
disease-free; as for the cases of recidivism, only three 
had been located in the peritoneum. The only prognos-
tic factor with statistical signiflcance was the number of 
liver nodulesfl>fl2. However, these flndings still need to 
be corroborated by other randomized studies with larger 
samples. Thus, well-selected patients, as long as they are 
submitted to treatment in specialized centers, can un-
dergo the simultaneous treatment of liver metastases and 
peritoneal carcinomatosis.  
REVERSE TREATMENT STRATEGY
Patients with synchronic liver metastases are classically 
submitted to primary tumor resection, followed by long 
CT periods and subsequently, if there is no disease pro-
gression during this period, they are referred to liver 
resection55,56. However, patients with advanced liver dis-
ease can have metastasis progression during the primary 
tumor treatment, making the lesions unresectable. This 
problem becomes especially important in patients with 
rectal tumors (who oflen necessary need to undergo 
neoadjuvant RT, in which the concomitant CT has only 
a radiosensitizing function) and in those with surgical 
complications caused by the primary tumor treatment. 
One strategy to attenuate this problem is to perform 
the liver resection together with the colorectal tumor re-
section. However, few patients are eligible for this proce-
dure and there are considerable limitations for extensive 
hepatectomies57,58.
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An attempt to overcome the problem has been the use 
of a new treatment strategy, called the reverse treatment 
strategy, where there is an inversion of the classic treat-
ment sequence59,60. 
Hence, liver metastases – the main determinants for 
the denition of the treatment curative characteristic – are 
treated before the primary tumor. Patients with asymp-
tomatic colorectal tumor with large, but resectable liver 
metastases or patients with initially unresectable metasta-
ses that achieved conversion aer chemotherapy are can-
didates to this type of treatment. 
In our service, we recommend starting these patients’ 
management with chemotherapy, aiming at the immediate 
treatment of both the liver metastases and the micrometa-
static systemic disease. The main concerns regarding this 
approach are the possibility of complications related to the 
primary tumor (pain, bleeding or obstruction) or the pro-
gression of liver metastases during the CT period. How-
ever, the rst is a rare event, not different from the rates of 
complications or bridle obstructions in patients submitted 
to surgery61,62, whereas the latter represents such a poor 
prognosis that these patients would hardly have beneted 
from any initial surgical treatment63. 
TREATMENT OUTCOMES 
Even considering the increase in surgical indications for 
larger tumors, multiple nodules, synchronous bilobar 
lesions and extrahepatic disease, one can observe an in-
crease in survival throughout the last decades, going in a 
period of ve years from 30% in the oldest series to more 
than 50% in the current ones (Table1).
A published analysis of 70 patients submitted to sur-
gery in our institution between January 1999 and June 
2005 showed a ve-year-survival of 51%64. A more recent 
reassessment of our series, taking into account 142 surger-
ies in 121 patients in recent years, showed a global survival 
of 66.2% in ve years and 54.9% in seven years (data not 
published). 
CONCLUSION
The perfecting of surgical techniques together with safer 
procedures, as well as the improvement in chemotherapy 
regimens have allowed doctors to offer patients with liver 
metastasis the possibility of curative treatment or long-
term survival. Factors that were previously considered 
contraindications for the surgery, such as number of me-
tastases, synchronous metastases and even the presence of 
extrahepatic disease, must be considered only as prognos-
tic factors and must not prevent the patient from having 
the opportunity of being treated. 
REFERENCES
1. Bouvier AM, Remontet L, Jougla E, Launay G, Grosclaude P, Velten 
M et al. Incidence of gastrointestinal cancers in France. Gastroen-
terol Clin Biol. 2004;28:877-81.
2. Faivre J, Manfredi S, Bouvier AM. Epidemiology of colorectal cancer 
liver metastases. Bull Acad Natl Med. 2003;187:815-22; discussion 
22-3.
3. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br 
J Surg. 1999;86:158-69.
4. Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemi-
ology in developing countries. Nat Rev Cancer 2004;4:909-17.
5. Welch JP, Donaldson GA. The clinical correlation of an autopsy 
study of recurrent colorectal cancer. Ann Surg. 1979;189:496-502.
6. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fu-
kuda H. Factors influencing survival of patients undergoing hepa-
tectomy for colorectal metastases. Br J Surg. 1999;86:332-7.
7. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR 
et al. Recurrence and outcomes following hepatic resection, radio-
frequency ablation, and combined resection/ablation for colorectal 
liver metastases. Ann Surg. 2004;239:818-25; discussion 25-7.
8. Ercolani G, Grazi GL, Ravaioli M, Cescon M Gardini A, Varotti G 
et al. Liver resection for multiple colorectal metastases: influence of 
parenchymal involvement and total tumor volume, vs number or lo-
cation, on long-term survival. Arch Surg. 2002;137:1187-92.
Table 1 – Outcomes  of liver resection for metastatic colorectal cancer
Author (year) Mortality % Mean survival (months) Five-year survival
Hughes et al. (1986) - Multicêntrico – – 33%
Gayowski et al. (1994) - Pittsburg Medical Center 0 33 32%
Jamison et al. (1997) - Mayo Clinic 4 33 27%
Fong et al. (1999) - Memorial Sloan Katering 3 42 36%
Choti et al. (2002) - Johns Hopkins 1 46 40%
Fernandez et al. (2004) - Washington University 1 – 59%
Pawlik et al. (2005) - M.D. Anderson 1 74 58%
Hospital A.C. Camargo (2005) 0 – 51%
Hospital A.C. Camargo (2010)
0.9 (30 days)
1.8 (90 days)
– 66.2%
ADVANCES IN THE SURGICAL TREATMENT OF COLORECTAL LIVER METASTASES
221Rev Assoc Med Bras 2011; 57(2):215-222
9. Adam R, Delvart V, Pascal G, Vallanu A, Castaing D, Azoulay D et 
al. Rescue surgery for unresectable colorectal liver metastases down-
staged by chemotherapy: a model to predict long-term survival. Ann 
Surg. 2004;240:644-57; discussion 57-8.
10. Giacchetti S, Itzhaki M, Gruia G. Long-term survival of patients with 
unresectable colorectal cancer liver metastases following infusional 
chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and sur-
gery. Ann Oncol. 1999;10:663-9.
11. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Frigilia N et 
al. Neoadjuvant treatment of unresectable liver disease with irinote-
can and 5-fluorouracil plus folinic acid in colorectal cancer patients. 
Ann Oncol. 2004;15:933-9.
12. Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Loyer R, Ellis LM 
et al. Body surface area and body weight predict total liver volume in 
Western adults. Liver Transpl. 2002;8:233-40.
13. Mosteller RD. Simplióed calculation of body-surface area. N Engl J 
Med. 1987;317:1098.
14. Busquets J, Pelaez N, Alonso S, Grande L. The study of cavitation-
al ultrasonically aspirated material during surgery for colorectal 
liver metastases as a new concept in resection margin. Ann Surg. 
2006;244:634-5.
15. Choti MA. Chemotherapy-associated hepatotoxicity: do we need 
to be concerned? Ann Surg Oncol. 2009;16:2391-4.
16. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, 
Strasberg SM. Five-year survival aóer resection of hepatic metas-
tases from colorectal cancer in patients screened by positron emis-
sion tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann 
Surg. 2004;240:438-47; discussion 47-50.
17. Lubezky N, Metser U, Geva R, Nakache R, Shmuele E, Klausner 
JM et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose 
positron emission tomography (FDG-PET) scan and computerized 
tomography (CT) in restaging patients with hepatic colorectal me-
tastases following neoadjuvant chemotherapy: comparison with op-
erative and pathological óndings. J Gastrointest Surg. 2007;11:472-8.
18. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger 
P, Irnagartinger G, Oberdorfer F et al. Fluorine-18-fluorouracil to 
predict therapy response in liver metastases from colorectal carci-
noma. J Nucl Med. 1998;39:1197-202.
19. Carnaghi C, Tronconi MC, Rimassa L, Tondulli L, Zuradelli M, Ro-
dari M et al. Utility of 18F-FDG PET and contrast-enhanced CT 
scan in the assessment of residual liver metastasis from colorectal 
cancer following adjuvant chemotherapy. Nucl Med Rev Cent East 
Eur. 2007;10:12-5.
20. Angliviel B, Benoist S, Penna C, El Hajjam M, Chagnon S, Julie C et 
al. Impact of chemotherapy on the accuracy of computed tomogra-
phy scan for the evaluation of colorectal liver metastases. Ann Surg 
Oncol. 2009;16:1247-53.
21. Benoist S, Brouquet A, Penna C, Angliviel B, Benoist S. Complete 
response of colorectal liver metastases aóer chemotherapy: does it 
mean cure? J Clin Oncol. 2006;24:3939-45.
22. Cohen MP, Machado MA, Herman P. Imapcto da ultrasonograóa 
intra-operatória nas cirurgias para ressecção de metástases hepáti-
cas. Arq Gastroenterol. 2005;42:206-12.
23. Lee WS, Kim MJ, Yun SH, Chung HK, Lee WY, Yun HR et al. Risk 
factor stratiócation aóer simultaneous liver and colorectal resec-
tion for synchronous colorectal metastasis. Langenbecks Arch 
Surg. 2008;393:13-9.
24. Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Adres A, Muratore 
A et al. Comparison between hepatic wedge resection and ana-
tomic resection for colorectal liver metastases. J Gastrointest Surg. 
2006;10:86-94.
25. Abdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey JN. Total and 
segmental liver volume variations: implications for liver surgery. 
Surgery 2004;135:404-10.
26. Vauthey JN, Chaoui A, Do KA, Bilimori MM, Hicks M, Alsfassie G 
et al. Standardized measurement of the future liver remnant prior 
to extended liver resection: methodology and clinical associations. 
Surgery 2000;127:512-9.
27. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM. Portal vein em-
bolization before right hepatectomy: prospective clinical trial. Ann 
Surg. 2003;237:208-17.
28. Madoff DC, Hicks ME, Abdalla EK, Morris JS, Vauthey JN. Por-
tal vein embolization with polyvinyl alcohol particles and coils 
in preparation for major liver resection for hepatobiliary malig-
nancy: safety and effectiveness--study in 26 patients. Radiology. 
2003;227:251-60.
29. Elias D, Lasser P, Rougier P, Ducreux M, Bognel C, Roche A. 
Frequency, technical aspects, results, and indications of major 
hepatectomy after prolonged intra-arterial hepatic chemother-
apy for initially unresectable hepatic tumors. J Am Coll Surg. 
1995;180:213-9.
30. Bismuth H, Adam R, Levi F, Farabos C, Waltcher F, Castaing D 
et al. Resection of nonresectable liver metastases from colorectal 
cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-
20; discussion 20-2.
31. Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P. Dur-
ing liver regeneration following right portal embolization the 
growth rate of liver metastases is more rapid than that of the liver 
parenchyma. Br J Surg. 1999;86:784-8.
32. Giacchetti S, Perpoint B, Zidani R, Le Bain N, Fagguiolo R, Focan 
C et al. Phase III multicenter randomized trial of oxaliplatin add-
ed to chronomodulated fluorouracil-leucovorin as first-line treat-
ment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-
47.
33. Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M. A 
multicenter evaluation of intensified, ambulatory, chronomodu-
lated chemotherapy with oxaliplatin, 5-fluorouracil, and leucov-
orin as initial treatment of patients with metastatic colorectal car-
cinoma. International Organization for Cancer Chronotherapy. 
Cancer 1999;85:2532-40.
34. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Brummer PD, Brienza 
A, Adam R et al. Biweekly intensified ambulatory chronomodu-
lated chemotherapy with oxaliplatin, fluorouracil, and leucov-
orin in patients with metastatic colorectal cancer. J Clin Oncol. 
1996;14:2950-8.
35. Levi F, Misset JL, Brienza S, Metzger G, Itzakhi M, Caussanel JP, 
et al. A chronopharmacologic phase II clinical trial with 5-fluo-
rouracil, folinic acid, and oxaliplatin using an ambulatory mul-
tichannel programmable pump. High antitumor effectiveness 
against metastatic colorectal cancer. Cancer 1992;69:893-900.
36. Kohne CH, Van Cutsem E, Wils J, Bokemeyer C, El Serafi M, Lutz 
MP et al. Phase III study of weekly high-dose infusional fluoro-
uracil plus folinic acid with or without irinotecan in patients with 
metastatic colorectal cancer: European Organisation for Research 
and Treatment of Cancer Gastrointestinal Group Study 40986. J 
Clin Oncol. 2005;23:4856-65.
37. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Kar-
asek P et al. Irinotecan combined with fluorouracil compared with 
fluorouracil alone as órst-line treatment for metastatic colorectal can-
cer: a multicentre randomised trial. Lancet 2000;355:1041-7.
38. Saltz LB, Cox JV, Blanke C, Rosen LS, Moore MH, Maroun JA et al. 
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal 
cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-14.
39. Tournigand C, Andre T, Achille E, Lledo G, Fresh M, Mery-Mignaro 
D et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in ad-
vanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 
2004;22:229-37.
40. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM et 
al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional 
Fluorouracil, and leucovorin: a pilot study in patients with metastatic 
colorectal cancer. J Clin Oncol. 2002;20:4006-14.
41. Adam R, Avisar E, Ariche A. Five-year survival following hepatic re-
section aóer neoadjuvant therapy for nonresectable colorectal. Ann 
Surg. Oncol. 2001;8:347-53.
42. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of 
colorectal liver metastases. World J Surg. 1995;19:59-71.
43. August DA, Sugarbaker PH, Schneider PD. Lymphatic dissemination 
of hepatic metastases. Implications for the follow-up and treatment of 
patients with colorectal cancer. Cancer 1985;55:1490-4.
44. Kokudo N, Sato T, Seki M, Ohta H, Azekura K, Ueno M et al. Hepatic 
lymph node involvement in resected cases of liver metastases from 
colorectal cancer. Dis Colon Rectum. 1999;42:1285-90; discussion 90-1.
FELIPE JOSÉ FERNÁNDEZ COIMBRA ET AL.
222 Rev Assoc Med Bras 2011; 57(2):215-222
45. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hägerstrand 
I, Ranstam J et al. Determinants of survival in liver resection for 
colorectal secondaries. Br J Surg. 1986;73:727-31.
46. Jaeck D, Nakano H, Bachellier P, Inoue K, Weber C, Oussoultzoglou 
E et al. Signiç cance of hepatic pedicle lymph node involvement in 
patients with colorectal liver metastases: a prospective study. Ann 
Surg Oncol. 2002;9:430-8.
47. Adam R, de Haas RJ, Wicherts DA, Aloia TA, Delvart V, Azoulay 
D et al. Is hepatic resection justiç ed aç er chemotherapy in patients 
with colorectal liver metastases and lymph node involvement? J Clin 
Oncol. 2008;26:3672-80.
48. Ashley AC, Deschamps C, Alberts SR. Impact of prognostic factors 
on clinical outcome aç er resection of colorectal pulmonary metasta-
ses. Clin Colorectal Cancer 2006;6:32-7.
49. Carpizo DR, DAngelica M. Liver resection for metastatic colorec-
tal cancer in the presence of extrahepatic disease. Lancet Oncol. 
2009;10:801-9.
50. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J 
et al. Peritoneal carcinomatosis from non-gynecologic malignancies: 
results of the EVOCAPE 1 multicentric prospective study. Cancer. 
2000;88:358-63.
51. Carpizo DR, DAngelica M. Liver resection for metastatic colorec-
tal cancer in the presence of extrahepatic disease. Ann Surg Oncol. 
2009;16:2411-21.
52. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on 
the eç cacy of cytoreductive surgery combined with perioperative 
intraperitoneal chemotherapy for peritoneal carcinomatosis from 
colorectal carcinoma. J Clin Oncol. 2006;24:4011-9.
53. Carmignani CP, Ortega-Perez G, Sugarbaker PH. The management 
of synchronous peritoneal carcinomatosis and hematogenous metas-
tasis from colorectal cancer. Eur J Surg Oncol. 2004;30:391-8.
54. Elias D, Benizri E, Pocard M, Ducreux M, Boige V, Lasser P. Treat-
ment of synchronous peritoneal carcinomatosis and liver metastases 
from colorectal cancer. Eur J Surg Oncol. 2006;32:632-6.
55. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, 
Schulik RD et al. Trends in long-term survival following liver resec-
tion for hepatic colorectal metastases. Ann Surg. 2002;235:759-66.
56. Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veihan 
LA et al. Long-term results of two-stage hepatectomy for irresectable 
colorectal cancer liver metastases. Ann Surg. 2008;248:994-1005.
57. Martin R, Paty P, Fong Y, Grace A, Cohen A, De Matteo R et al. Simulta-
neous liver and colorectal resections are safe for synchronous colorectal 
liver metastasis. J Am Coll Surg. 2003;197:233-41; discussion 41-2.
58. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribeiro D, Assumpção 
L et al. Simultaneous resections of colorectal cancer and synchro-
nous liver metastases: a multi-institutional analysis. Ann Surg On-
col. 2007;14:3481-91.
59. Brouquet A, Mortenson MM, Vauthey JN, Abdalla EK. Surgical 
strategies for synchronous colorectal liver metastases in 156 consec-
utive patients: classic, combined or reverse strategy? J Am Coll Surg. 
2010;210:934-41.
60. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth 
AD. Neoadjuvant chemotherapy and resection of advanced synchro-
nous liver metastases before treatment of the colorectal primary. Br J 
Surg. 2006;93:872-8.
61. Poultsides GA, Servais EL, Saltz LB, Patil S, Kameny NE, Guillem JG 
et al. Outcome of primary tumor in patients with synchronous stage 
IV colorectal cancer receiving combination chemotherapy without 
surgery as initial treatment. J Clin Oncol. 2009;27:3379-84.
62. Tebbutt NC, Norman AR, Cunningham D, Andreyev J. Intesti-
nal complications aç er chemotherapy for patients with unresect-
ed primary colorectal cancer and synchronous metastases. Gut. 
2003;52:568-73.
63. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B et 
al. Tumor progression while on chemotherapy: a contraindication 
to liver resection for multiple colorectal metastases? Ann Surg. 
2004;240:1052-61; discussion 61-4.
64. Herman P, Machado MAC, Diniz AL, Coimbra FJF, Sallum RA, 
Montagnini AL. Surgical treatment of colorectal cancer hepatic me-
tastases; experience of A. C. Camargo Cancer Hospital - São Paulo. 
Appl Cancer Res. 2006;26:88-93.
